SRPT - Sarepta upgraded at Oppenheimer on potential Elevidys label expansion
2024-05-14 09:00:16 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
- Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
- Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts
- HHS panel to vote in Nov. on DMD screening for newborns
- Sarepta Elevidys accelerated approval criticized by ICER exec